STOCK TITAN

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) is set to present and host meetings at the 2023 BIO CEO & Investor Conference in New York from February 6-9, 2023. CEO Steve Worland will discuss the clinical development pipeline and corporate strategy on February 6 at 2:15 PM ET at the New York Marriott Marquis. The company specializes in selective translation regulator inhibitors (STRIs) aimed at treating cancer, focusing on their lead drug tomivosertib, which is in a Phase 2b trial for non-small cell lung cancer. eFFECTOR also collaborates with Pfizer on eIF4E inhibitors and investigates zotatifin for COVID-19 treatment.

Positive
  • None.
Negative
  • None.

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY.

Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company’s clinical development pipeline and corporate strategy. The presentation will be given in-person at the New York Marriott Marquis on Monday, February 6th at 2:15 PM ET.

Interested participants may register to access eFFECTOR Therapeutics’ presentation and the entire conference on the BIO CEO & Investor Conference event website at https://www.bio.org/events/bio-ceo-investor-conference.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed antiviral therapy in patients with mild to moderate COVID-19 in collaboration with UCSF, which holds a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.

Contacts:

Investors: Media:
Christopher M. Calabrese
Managing Director
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com
Heidi Chokeir, Ph.D.
Managing Director
Evoke Canale
619-203-5391
Heidi.chokeir@evokegroup.com


FAQ

What is eFFECTOR Therapeutics' role in the 2023 BIO CEO & Investor Conference?

eFFECTOR Therapeutics will present its clinical development pipeline and corporate strategy at the conference from February 6-9, 2023.

When will eFFECTOR's presentation take place at the BIO CEO & Investor Conference?

eFFECTOR's presentation will occur on February 6, 2023, at 2:15 PM ET.

What is the ticker symbol for eFFECTOR Therapeutics?

The ticker symbol for eFFECTOR Therapeutics is EFTR.

What is tomivosertib and its current trial status?

Tomivosertib is eFFECTOR's lead product candidate, currently in a Phase 2b trial for metastatic non-small cell lung cancer.

How is zotatifin being evaluated by eFFECTOR Therapeutics?

Zotatifin is being tested in Phase 2a expansion cohorts in biomarker-positive solid tumors and for COVID-19 treatment.

EFFECTOR THERAPUTCS INC

OTC:EFTR

EFTR Rankings

EFTR Latest News

EFTR Stock Data

611.57k
4.70M
2.91%
21.73%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH